Fundsmith Reduces $9M in Medpace Holdings, Inc. ($MEDP)
Key Points
- Fundsmith changed its Medpace Holdings, Inc. ($MEDP) stake by 24.1% last quarter, cutting to 62,668 shares worth $29.29 million.
- Wall Street's consensus rating on $MEDP is Hold and an average price target of $442.83.
- $MEDP last traded around $467.43.
Fundsmith reduced its position in Medpace Holdings, Inc. ($MEDP) by 24.1% during the most recent quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 62,668 shares of Medpace Holdings, Inc. after selling 19,899 shares during the quarter. Fundsmith's holdings in Medpace Holdings, Inc. were worth $29.29 million as of its most recent filing.
Medpace Holdings, Inc. ($MEDP) Stock
Medpace Holdings, Inc. Earnings
Analysts Set New Price Targets
About Medpace Holdings, Inc.
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, Asia, South America, Africa, and Australia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, the company offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Medpace Holdings, Inc. was founded in 1992 and is based in Cincinnati, Ohio.
See Also
This instant news alert was generated by automated narrative technology and financial data from Trueearnings and public regulatory filings. It is for informational purposes only and is not financial advice.